Oral Cladribine Capsules for Generalized Myasthenia Gravis: Design of the Actively Recruiting Phase 3 MyClad Study (P1-11.013)
To evaluate the efficacy and safety of a new oral formulation of cladribine versus placebo in generalized myasthenia gravis (gMG).
Authors
- Jacqueline Palace (ORCID: https://orcid.org/0000-0002-2934-9383)
- Nektaria Alexandri (ORCID: https://orcid.org/0000-0002-9806-8358)
- Sathej Gopalakrishnan (ORCID: https://orcid.org/0000-0003-0923-034X)
- Kevin C. O’Connor (ORCID: https://orcid.org/0000-0002-7056-419X)
- Andrija Javor (ORCID: https://orcid.org/0000-0002-6285-8104)
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- Gary Cutter (ORCID: https://orcid.org/0000-0002-8455-980X)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Mazen M. Dimachkie (ORCID: https://orcid.org/0000-0002-7148-989X)
- Axel Nolting (ORCID: https://orcid.org/0000-0002-7480-113X)
- Konrad Rejdak (ORCID: https://orcid.org/0000-0002-7019-6681)
- Andreas Meisel (ORCID: https://orcid.org/0000-0001-7233-5342)
- Henry J. Kaminski (ORCID: https://orcid.org/0000-0002-8195-0141)
- Claire Le Bolay
- Dominic Jack (ORCID: https://orcid.org/0000-0001-8629-553X)
Institutions
- University of North Carolina at Chapel Hill (US)
- Medical University of Lublin (PL)
- Merck KGaA, Darmstadt (Germany) (DE)
- George Washington University (US)
- University of Alabama at Birmingham (US)
- Yale University (US)
- University of Oxford (GB)
- University of Kansas Medical Center (US)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208638
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00